Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lauren Schaff

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Continuum (Minneapolis, Minn.)|December 12, 2023
Central Nervous System LymphomaLauren Schaff
Leukemia & Lymphoma|April 10, 2024
Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advancesLauren Schaff, Lakshmi Nayak, Christian Grommes
Annals of Lymphoma|April 17, 2023
Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohortPrakirthi Yerram, Samantha N Reiss, Lisa Modelevsky, et al.
Cancer Chemotherapy and Pharmacology|March 13, 2025
New recommendations for reversal of high-dose methotrexate cytotoxicity with folinic acidJesper Heldrup, Archie Bleyer, Laura Ramsey, et al.
Cancer Chemotherapy and Pharmacology|July 25, 2025
Retraction Note: New recommendations for reversal of high-dose methotrexate cytotoxicity with folinic acidJesper Heldrup, Archie Bleyer, Laura Ramsey, et al.
Neuro-Oncology|June 25, 2024
Outcomes and relapse patterns in primary central nervous system lymphoma: Longitudinal analysis of 559 patients diagnosed from 1983 to 2020Kathryn R Tringale, Michael Scordo, Joachim Yahalom, et al.
Brain Pathology (Zurich, Switzerland)|January 28, 2020
Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2-wildtype astrocytomasAndrew L Lin, Marc Rosenblum, Ingo K Mellinghoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2022
Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal MetastasesN Ari Wijetunga, Alexander G Goglia, Nils Weinhold, et al.
Neuro-Oncology|June 28, 2020
Clinical trial of proton craniospinal irradiation for leptomeningeal metastasesT Jonathan Yang, Neil A Wijetunga, Josh Yamada, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 25, 2025
Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal MetastasesMonica F Chen, Jake June-Koo Lee, Noura J Choudhury, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Continuum (Minneapolis, Minn.)|December 12, 2023
Central Nervous System LymphomaLauren Schaff
Leukemia & Lymphoma|April 10, 2024
Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advancesLauren Schaff, Lakshmi Nayak, Christian Grommes
Annals of Lymphoma|April 17, 2023
Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohortPrakirthi Yerram, Samantha N Reiss, Lisa Modelevsky, et al.
Cancer Chemotherapy and Pharmacology|March 13, 2025
New recommendations for reversal of high-dose methotrexate cytotoxicity with folinic acidJesper Heldrup, Archie Bleyer, Laura Ramsey, et al.
Cancer Chemotherapy and Pharmacology|July 25, 2025
Retraction Note: New recommendations for reversal of high-dose methotrexate cytotoxicity with folinic acidJesper Heldrup, Archie Bleyer, Laura Ramsey, et al.
Neuro-Oncology|June 25, 2024
Outcomes and relapse patterns in primary central nervous system lymphoma: Longitudinal analysis of 559 patients diagnosed from 1983 to 2020Kathryn R Tringale, Michael Scordo, Joachim Yahalom, et al.
Brain Pathology (Zurich, Switzerland)|January 28, 2020
Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2-wildtype astrocytomasAndrew L Lin, Marc Rosenblum, Ingo K Mellinghoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2022
Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal MetastasesN Ari Wijetunga, Alexander G Goglia, Nils Weinhold, et al.
Neuro-Oncology|June 28, 2020
Clinical trial of proton craniospinal irradiation for leptomeningeal metastasesT Jonathan Yang, Neil A Wijetunga, Josh Yamada, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 25, 2025
Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal MetastasesMonica F Chen, Jake June-Koo Lee, Noura J Choudhury, et al.
Pageof 2